Answers are grounded in this paper and cite their sources.
This cross-sectional study examines patients’ out-of-pocket costs with and without rebate pass-through to point-of-sale prices for cancer drugs under Medicare Part D.
No takes yet. Share an insight, caveat, or question.
Hwang et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: